Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com

Neurizon Commences Trading on OTCQB Venture Market to Facilitate Access to U.S. Investors

Highlights:

- **Neurizon® Therapeutics' common shares approved for trading on the OTCQB® Venture Market in the U.S. under code NUZTF effective 8 October 2025 (AEDT)**
- **OTCQB quotation allows U.S. investors to trade NUZ's ordinary shares in USD during U.S. market hours and is expected to increase liquidity across primary ASX trading via NUZ and NUZOA and improve visibility across a larger international market**
- **Leading U.S. investor relations firm with deep life sciences expertise, Integrous Communications appointed to strengthen Neurizon's North American capital markets presence**
- **Broader expansion into U.S. market follows positive industry and investor engagement, ahead of planned entry into HEALEY ALS Platform Trial, expected to commence in Q4 CY2025**

8 October 2025 – Melbourne Australia: Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech comp any dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to advise that the Company's common shares have been approved for trading on the OTCQB® Venture Market in the United States under the code NUZTF, effective 8 October 2025 (AEDT). The Company's shares will continue to trade on the Australian Securities Exchange (ASX).

Being quoted on the OTCQB® Venture Market will allow U.S. investors to trade NUZ's ordinary shares in U.S. dollars during U.S. market hours, while the Company maintains its primary listing on the ASX via codes NUZ and NUZOA. The new quotation further expands Neurizon's presence in the world's largest healthcare and capital markets at a critical time in its growth trajectory and is expected to provide greater transparency and liquidity to its primary listing on the ASX. This milestone reinforces Neurizon's commitment to best practices, while broadening its global investor base to unlock long-term value for shareholders.

To further strengthen Neurizon's U.S. market presence and facilitate access to new investor groups, the Company has engaged Integrous Communications, a leading North American investor relations and strategic communications firm with deep life sciences expertise. The group will lead pending North American investor relations initiatives, including communicating Neurizon's corporate, financial, clinical development and pipeline expansion progress to U.S. shareholders and prospective investors, complementing its ASX presence and strengthening the Company's visibility in global capital markets.

Managing Director and Chief Executive Officer, Dr Michael Thurn commented: "Neurizon has always been committed to advancing neurogenerative therapies on a global scale, and quotation on the OTCQB provides a significant opportunity to broaden our exposure to U.S. investors and the world's largest pharmaceutical market. The U.S. capital markets are recognized for their strong focus on healthcare and biotechnology, and we believe this will enhance Neurizon's visibility and appeal to a broader base of institutional and retail investors.

We are grateful for the outstanding support of our Australian stakeholders and the ASX, which will remain the Company's primary listing. Importantly, we see the OTCQB quotation as highly complementary to our existing platform, strengthening the work already undertaken on the ASX and positioning Neurizon to access deeper pools of capital as we progress into the next phase of growth. We look forward to working closely with the team at Integrous to maximise the benefits of this dual-market presence."

Matthew Selinger, Senior Partner at Integrous commented: "Neurizon is entering a pivotal phase in the development of NUZ-001, a potentially life-changing treatment for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases**.** Following strong safety, tolerability, and efficacy signals demonstrated in both pre-clinical and clinical studies, the company is set to initiate the HEALEY ALS Platform Trial in the upcoming fourth quarter—an important step that may accelerate the pathway to regulatory approval. In parallel, Neurizon has secured a global licensing agreement with Elanco, laying the foundation for future commercialization. We believe the company has a compelling platform and look forward to bringing their story to broader markets."

The OTCQB® Venture Market provides an established platform for early-stage and growth companies to enhance their visibility in the U.S. market. Companies listed on OTCQB must meet rigorous reporting standards, undergo annual verification, and comply with management certification requirements, providing investors with a trusted market for trading. Real-time quotes and market information on Neurizon can be found at www.otcmarkets.com.

-ENDS-

This announcement has been authorized for release by the Board of Neurizon Therapeutics Limited.

For further information, please contact:

Neurizon Therapeutics
Lidija Damjanovic
Marketing & Corporate Affairs
Email: lidija@neurizon.com
Phone: +61 (0) 425 700 504

Australia Investor Relations
Henry Jordan
Six Degrees Investor Relations
Email: henry.jordan@sdir.com.au
Phone: +61 (0) 431 271 538

U.S. Investor Relations
Matthew Selinger
Integrous Communications
Email: mselinger@integcom.us
Phone: +1 415-572-8152

About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction.

About Integrous Communications

Integrous Communications is an independent communications and investor relations consulting firm which provides integrated corporate communications services. Headquartered in Austin, Texas with locations across the US and Canada, the firm's diverse team of professionals has more than 100 plus years of combined experience. Integrous serves both domestic and international clients, including companies listed on the U.S., Canadian, Australian, and European exchanges.

About the Healy ALS Trial

The Healey ALS Trial is a perpetual multi-center clinical trial testing multiple investigational drugs for Amyotrophic Lateral Sclerosis (ALS) simultaneously using a platform trial design to accelerate the development of potential treatments. It employs a common protocol and infrastructure to efficiently evaluate new drugs, randomizing participants to different treatment "regimens" and providing a placebo-controlled environment followed by an open-label extension where participants receive the active drug long-term. The trial aims to find safe and effective treatments and has enrolled many participants at sites across the U.S.

Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com

Neurizon Investor Hub

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon.
This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

To access Neurizon Investor Hub please scan the QR code or visit https://investorhub.neurizon.com

Neurizon® is a registered trademark of Neurizon Therapeutics Limited
OTCQB® Venture Market is a registered trademark of OTC Markets Group Inc.